Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Fariborz (Fred) Mortazavi, M.D.
Fariborz (Fred) Mortazavi, M.D.

Specialty:

Hematology/Oncology

General Information:

Gender:
Male
Language(s):
English and Farsi

Affiliation(s):

Assistant Professor in Residence, Department of Medicine
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

West Los Angeles Veterans Affairs Medical Center

Education:

Fellowship:
University of Illinois at Chicago, 2003 - 2006
Research Fellowship:
Memorial Sloan Kettering Cancer Center, 2002 - 2003
Residency:
St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, 2000-2002
Internship:
Mt. Sinai Medical Center, 1999-2000
Medical Degree:
M.D., Tehran University of Medical Sciences, Tehran, Iran, 1994

Certification(s):

Medical Board Certification(s):
Medical Oncology, American Board of Internal Medicine, 2006
Hematology, American Board of Internal Medicine, 2006
Internal Medicine, American Board of Internal Medicine, 2002

Contact Information:

Phone:
(310) 268-4567
Email:

Practice Information:

Clinical Interest(s):
Thoracic malignancies

Scientific Interest(s):

Studying the signaling pathways that promote invasion and metastasis in lung cancer is currently the focus of Dr. Fred Mortazavi's research. For example, as part of the adherens junction, p120-catenin (p120ctn) plays an important role in the stability of cell-cell adhesions and downregulation of the p120-catenin is reported in a large proportion (60-80%) of non-small cell lung cancer (NSCLC) cases. Mortazavi and others reported that p120-catenin is transcriptionally downregulated in NSCLC and identified two signaling pathways that mediate p120-catenin repression. Identifying the prometastatic signaling events in cancer cells could pave the way for the future interventions in order to stop the metastatic process.

Selected Cancer-Related Publications:

Mortazavi F, Dubinett S, Rettig M. c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells. Clin Exp Metastasis. 2011 Apr;28(4):391-404. Epub 2011 Feb 20.

Mortazavi F, An J, Dubinett S, Rettig M. p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells. Mol Cancer Res. 2010 May;8(5):762-74. Epub 2010 May 11.